Adaptyv Bio launches its protein-engineering platform

Identifying new antibodies is fundamental in fighting diseases such as viral infections, autoimmune diseases, and cancers. Unfortunately, the current process for testing the efficacy of new antibodies is slow and expensive and has a failure rate of around 88%.

Combining robotics, microfluidics and synthetic biology techniques, Adaptyv Bio is building a full-stack platform – protein foundry – that allows protein engineers to design and test new proteins and generate data about their proteins in order to develop new medicines, better enzymes for research and industrial applications or functional materials with novel properties.

To enable that tight feedback loop from computational design to experimental validation, Adaptyv is innovating on all levels of the technology stack: from custom synthetic biology techniques for designing DNA, synthesizing proteins and assaying them, to novel lab-on-chip modular work cells that can replace multiple commercial instruments at once, to advanced lab robotics that allow the company to run experiments autonomously. This will reduce reagent consumption, time per experiment and thus cost per data point generated by multiple orders of magnitude compared to today’s approaches.

With the launch of its lab-as-a-service platform, Adaptyv is now opening up its platform to protein engineers through an early access program. With already paying customers using the platform, Adatyv plans to expand its lab operations, on-board more customers and expand the suite of experiments in the next phase.

Based in Lausanne at the Biopole Life Sciences Campus, Adaptv Bio participated in the Y-Combinator program in 2021 and raised a pre-seed round led by Wingman Ventures. The startup has since grown the team to 12 engineers.

(Press release/RAN)